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AbstrACt
Objectives To estimate the proportion of adult primary 
care outpatients who are clinically detected and initiate 
treatment for depression and alcohol use disorder (AUD) in 
low-income and middle-income country (LMIC) settings.
Design Five cross-sectional studies.
setting Adult outpatient services in 36 primary healthcare 
facilities in Sodo District, Ethiopia (9 facilities); Sehore 
District, India (3); Chitwan District, Nepal (8); Dr Kenneth 
Kaunda District, South Africa (3); and Kamuli District, 
Uganda (13).
Participants Between 760 and 1893 adults were 
screened in each district. Across five districts, between 
4.2% and 20.1% screened positive for depression and 
between 1.2% and 16.4% screened positive for AUD. 96% 
of screen-positive participants provided details about their 
clinical consultations that day.
Primary outcomes Detection of depression, treatment 
initiation for depression, detection of AUD and treatment 
initiation for AUD.
results Among depression screen-positive participants, 
clinical detection of depression ranged from 0% in India 
to 11.7% in Nepal. Small proportions of screen-positive 
participants received treatment (0% in Ethiopia, India and 
South Africa to 4.2% in Uganda). Among AUD screen-
positive participants, clinical detection of AUD ranged from 
0% in Ethiopia and India to 7.8% in Nepal. Treatment was 
0% in all countries aside Nepal, where it was 2.2%.
Conclusions The findings of this study suggest large 
detection and treatment gaps for adult primary care 
patients, which are likely contributors to the population-
level mental health treatment gap in LMIC. Primary care 
facilities remain unfulfilled intervention points for reducing 
the population-level burden of disease in LMIC.
bACkgrOunD 
Mental, neurological and substance use disor-
ders (MNS) contribute significantly to the 
Global Burden of Disease and account for 
1 in every 10 lost years of health globally.1 
In 2010, the absolute disability-adjusted life-
years (DALYs) due to MNS disorders was 
258 million DALYs, which was 10.4% of the 
total disease burden. MNS disorders were also 
the leading cause of years lived with disability 
globally.1 In addition, MNS disorders act as a 
significant risk factor for premature death2 
and also account for substantial adverse social 
and economic consequences.1 3 Depression 
accounts for 40.5% of DALYs caused by mental 
and substance use disorders while alcohol use 
disorders (AUDs) account for 9.6%.4 
In low-income and middle-income coun-
tries (LMICs) the population-level treatment 
gap is estimated to be between 76.3% and 
91.9% for depression and between 94.9% 
and 97.2% for AUD.5 There is an emerging 
evidence base demonstrating that depres-
sion and AUD can be treated by primary 
care providers in LMIC6; WHO’s mhGAP 
guidelines support integration of mental 
health services into primary care as a means 
of narrowing the treatment gap.7 People 
affected by depression and AUD often present 
strengths and limitations of this study
 ► This was a multicountry survey of diverse clinical 
settings, with large sample sizes, structured inter-
views and used of validated screening tools to iden-
tify cases.
 ► The methods used here are demonstrably flexible 
and are replicable in other low-income settings, 
particularly for monitoring and evaluation purposes.
 ► We used highly sensitive and non-specific coding 
criteria for our primary outcomes (ie, detection and 
treatment initiation), and so outcome misclassifica-
tion is possible.
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in primary health care facilities8 9 though not specifi-
cally for these disorders. These disorders co-occur with 
both acute and chronic medical problems; an untreated 
mental health disorder worsens the prognosis for the 
comorbid condition.10 11 The population-level treatment 
gap can be reduced by enhancing the capacity of primary 
care staff to detect, diagnose and treat these disorders.12 
Clinical detection of depression is estimated to be 47% 
from a meta-analysis of 41 studies conducted in primary 
care settings13 and 42% for AUD from a meta-analysis of 
12 studies.14 However, these meta-analyses were not able 
to identify studies conducted in LMIC settings, where the 
majority of people with depression and AUD in the world 
live, and where a paucity of mental health in the pre-ser-
vice training of general health care providers as well as 
competing demands in under-resourced health care 
systems likely compromise the ability of clinicians to detect 
mental disorders. Little is therefore known regarding the 
detection levels of depression and AUD in primary care 
settings in LMICs.
The aims of this report were to estimate the propor-
tion of adult primary care outpatients who are clini-
cally detected and initiate treatment for depression and 
for AUD in LMIC settings.
MethODs
Context, setting and participants
PRIME is a 6-year multicountry research programme 
consortium which, in collaboration with national and 
district Ministries of Health, has developed Mental 
Health Care Plans to support delivery of services for 
mental disorders in the public sector in Ethiopia (Sodo 
District), India (Sehore District, Madhya Pradesh State), 
Nepal (Chitwan District), South Africa (Dr Kenneth 
Kaunda District, North West Province) and Uganda 
(Kamuli District).15 16 Two key research questions of the 
PRIME evaluation, detailed in a separate report,17 were 
to assess the change in detection and change in initia-
tion of treatment among adults presenting in primary 
health facilities, as a consequence of implementing the 
district mental health care plans. These questions were 
investigated by conducting cross-sectional facility-based 
patient surveys before and after the mental health care 
plan implementation. The two populations of interest for 
the study were the adult patients who screened positive 
(1) for depression and (2) for AUD.
Details about the study settings and clinics are in table 1.
The choice of included clinics was determined by the 
availability of staff who were planned to have authority to 
detect/diagnose, prescribe and/or refer for depression 
Table 1 Geographic and health facility characteristics of PRIME implementation areas, 2013–2014
Country Ethiopia India Nepal South Africa Uganda
Implementation 
area
Sodo District Sehore and 
Shyampur 
subdistricts of 
Sehore District, 
Madhya Pradesh
Chitwan District* Orkney catchment 
area of Matlosana 
subdistrict of Dr 
Kenneth Kaunda 
District, Northwest 
Province
Kamuli District
Population 161 952 212 192 108 368 90 000 518 200
Area, km2 867 1039 342 31 4278
# and type of 
health facility
8 public and 1 
private health 
clinics
3 CHC 9 health posts and 1 
PHC†
1 CHC and 3 PHC 
clinics‡
12 health centres 
(levels III and IV)
1 primary care 
department in the 
district hospital
Primary provider 
types
Health officer Medical officer Medical officers, 
health assistants, 
auxiliary health 
workers
Nurse, PHC doctor Medical officer
Primary care 
services provided 
in the facilities
Primary care, 
emergency; delivery 
care, mother and 
baby care, family 
planning and 
immunisation
Primary, acute, 
reproductive and 
child health
Outpatient; 
immunisation; 
family planning; 
safe motherhood 
and new born 
care; antinatal and 
postnatal care; 
delivery of babies
Chronic care Outpatient; emergency; 
immunisation; maternal 
and child health; 
family planning, 
health education and 
primary care in general 
including mental health
*Implementation area consists of 10 of the 38 Village Development Committees/Municipalities of Chitwan District.
†222 study participants from 2 of the 10 health facilities are excluded from analysis.
‡One of the three PHC clinics was an implementation pilot site and was excluded from study data collection.
CHC, community health centre; PHC, primary health care centre. 
 o
n
 17 O
ctober 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-023421 on 10 October 2018. Downloaded from 
3Rathod SD, et al. BMJ Open 2018;8:e023421. doi:10.1136/bmjopen-2018-023421
Open access
and AUD, which, per the respective country’s mental 
health care plan included clinics with health officers, 
medical officers, health assistants and auxiliary health 
workers, nurses and doctors. In South Africa, one of the 
PHC clinics was excluded from the study due to mental 
health care plan training occurring prior to the baseline 
survey round. In South Africa, nurses in the primary care 
clinics could refer suspected cases to a physician (for both 
disorders) and provide brief counselling (for non-de-
pendent AUD) and so these clinics were included. Only 
patients attending for chronic care services (eg, HIV, 
tuberculosis, diabetes, hypertension, etc) were eligible 
for this study, reflecting eligibility for treatment in accor-
dance with the South African mental health care plan. In 
Nepal, clinicians working in two clinics received mental 
health training prior to the baseline survey round; these 
clinics are included for clinical-level descriptive reporting 
but participants from these clinics are excluded for anal-
ysis here. All clinics were government run, aside one in 
Ethiopia.
sample size
For each country and disorder the sample size was set to 
have 80% power and a two-sided alpha of 0.05 for the two 
primary aims: (1) to detect a change in detection and (2) 
to detect a change in initiation of evidence-based treat-
ment for depression and for AUD between the baseline 
and follow-up round. The baseline round was set prior 
to implementation of the mental health care plan and 
follow-up round was scheduled to start at least 18 months 
later, which assumed the plan had been fully embedded 
for several months. Country teams in Nepal and Uganda 
planned to conduct an interim survey round immedi-
ately after embedding, to assess the short-term effect of 
implementation on detection and treatment. Findings 
from interim and follow-up surveys will be detailed in 
future reports. Depending on country, the baseline level 
of detection was assumed to be 0%–5%, and at follow-up 
targeted to reach 20%–30%. The required sample size 
was adjusted to account for the possibility of false positives 
generated by screening tools, using site-specific figures for 
the positive predictive value. Within each country, which-
ever disorder required the higher sample size dictated 
the sample size. This sample size was increased by a factor 
of 2–3× to facilitate equity analyses, for example, compar-
isons of outcomes by sex or by socioeconomic status. The 
target sample sizes for each country in each study round 
were 1000 in Ethiopia, 760 in India, 1400 in Nepal, 1200 
in South Africa and 1800 in Uganda. Within each country 
the total target sample size was then allocated by clinic in 
proportion to measures of clinic outpatient volume, such 
that busier clinics were allocated a larger recruitment 
target than less busy clinics.
Details of the sampling and data collection procedures 
are given in table 2.
sampling and recruitment
Inclusion criteria for participation were as follows: above 
age of majority in the country (ie, 16 years or 18 years); 
fluency in a local study language; time and ability to 
complete the full interview; and willingness to provide 
informed consent. Exclusion criteria were as follows: 
incapacity to provide informed consent (eg, presence of 
severe intellectual disability, currently experiencing an 
acute medical issue). The research team for each country 
trained its interviewers to assess eligibility.
Logistic and cultural constraints dictated the sampling 
procedure within each country, meaning that random 
selection for a representative sample was not always 
possible. In Ethiopia and Uganda, to minimise disrup-
tion, consecutive sampling of all eligible patients on regis-
tration minimised the amount of time research staff spent 
in the clinics. In South Africa, research staff provided a 
group orientation to the study to all patients in the waiting 
room, and then asked interested patients to self-nominate 
for recruitment. In India, research assistants approached 
every fifth patient registering at reception and assessed 
them for eligibility. Among eligible patients approached, 
>94% consented to participate in all countries.
Data collection procedures
The facility interview comprised a screening question-
naire, an exit questionnaire and/or a clinical consultation 
form. Interviewers administered the two-part screening 
questionnaire, with part 1 used to identify probable cases. 
For probable cases and optionally for probable non-cases, 
interviewers completed part 2 of the screening ques-
tionnaire. For these same participants, the interviewer 
completed the exit questionnaire with the participant 
and/or requested a consultation form from that partic-
ipant’s clinician. In Uganda, patients maintained their 
own medical files in a notebook which is handed over to 
clinicians during consultations, and so the clinical consul-
tation form data were synonymous with exit questionnaire 
data. The data collection flow chart for each country is 
shown in online supplementary figures 1a-1e.
The sections within the screening interview question-
naire are described in table 3.
Data collection measures
Part 1 of the screening questionnaire consisted of sections 
on sociodemographic characteristics, screening for 
depression, depression symptoms in the past 12 months 
(aside in Ethiopia) and screening for AUD. A probable 
case of depression was a participant who was Patient's 
Health Questionnaire (PHQ-9) positive or had recent 
depression symptoms, and a probable case of AUD was a 
participant who was Alcohol Use Disorder Identification 
Test (AUDIT) positive. Probable cases completed disor-
der-specific sections about recent (12 months) history of 
treatment seeking for their most recent episode of symp-
toms, and about internalised stigma. Part 2 consisted 
sections about sociodemographic characteristics and 
disability status. The exit questionnaire and clinical 
consultation form were thematically similar, and consisted 
of a mix of open-ended and closed-ended questions 
about that day’s clinical consultation, and specifically 
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about diagnoses, advice, referrals and prescriptions. Each 
country developed their own exit questionnaire and clin-
ical consultation form to enable data collection by inter-
viewers with the participant and by the clinician directly, 
respectively, in recognition of the context-specific nature 
of patient–clinician interactions and the local idioms of 
distress. In addition to the questionnaire items described 
here, which were largely consistent across PRIME country 
sites, research teams included country-specific questions 
and sections, which will be described in future reports. 
See PRIME website (http://www. prime. uct. ac. za) for the 
purpose-built sections of the PRIME questionnaires.
Mental health measures
The denominators for the primary outcome measures 
consist of those participants who screen positive for 
depression or for AUD using the PHQ-9 and AUDIT, 
respectively. The PHQ-9 is a widely used screening tool 
that has been validated for use in all five countries.18–22 
In this study, Cronbach’s alpha for the PHQ-9 ranged 
between 0.74 in India and 0.80 in Nepal. A score of 10 
or more on the PHQ-9 screen was considered a positive 
screen. The AUDIT tool has been validated in India, 
Nepal and South Africa23–25 and in countries neigh-
bouring Uganda.26 27 In this study, Cronbach’s alpha for 
AUDIT ranged from 0.66 in Uganda to 0.88 in Nepal. An 
AUDIT score of ≥20 was considered to indicate alcohol 
dependence, while scores of 16–19 and 8–15 were classi-
fied as harmful and hazardous drinking, respectively. A 
score of 8 or more in Ethiopia, India and Uganda, 9 or 
more in Nepal and 16 or more in South Africa was consid-
ered a positive screen. The higher cut-off score in South 
Africa was set to account for services being targeted to 
those with harmful and dependent alcohol use.
Outcome assessment
The numerators for the primary outcome measures were 
derived from participant exit questionnaire data when 
available (India, Nepal, South Africa, Uganda), and 
alternatively from the clinician consultation form data 
(Ethiopia). Given the sparse level of detail patients were 
expected to recall and/or clinicians were expected to 
record, cross-country variation in the terminology around 
detection and treatment, as well as expected low levels 
Table 2 Sample selection and data collection procedures for facility surveys, 2013–2014
Country site Ethiopia India Nepal South Africa Uganda
Survey dates June–July 2013 August–October 
2013
September 2013–
February 2014
February–April 2014 July–November 
2013
Study language Amharic Hindi Nepali English, seTswana English, Luganda
Recruitment/sampling 
method
Consecutive 
sampling of adults 
at registration
Systematic 
sampling of every 
fifth adult at 
registration
Random selection of 
one adult from those 
who arrived since 
last interview started
Opportunistic 
sampling of adult 
volunteers in 
chronic care clinic 
waiting area
Consecutive 
sampling of adults 
at registration
Consent documented 
with
Signature or 
thumbprint
Signature or 
thumbprint
Signature or verbal 
affirmation
Signature or signed 
‘X’ with independent 
witness signature
Signature or verbal 
affirmation.
# approached 1014 760 1553 9780 1922
# eligible 1014 760 1553 1322 1922
# consented (% 
consent rate)
1014 (100) 760 (100) 1474 (94.9) 1322 (100) 1893 (98.5)
Questionnaire data 
collection mode
Paper-and-pencil, 
double data entry 
with EpiData 3
Android mobile 
device
Android mobile 
device
Android mobile 
device
Android mobile 
device
Depression screen 
positive is Patient’s 
Health Questionnaire 
>=
10 10 10 10 10
Alcohol use disorder 
screen positive is 
Alcohol Use Disorder 
Identification Test >=
8 8 9 16 8
Clinical consultation 
form
Purpose-built 
form
Extracted from 
clinical records 
maintained at the 
facility
Purpose-built form Extracted from clinic 
records
Consultation notes 
extracted from 
patient’s notebook 
as part of the exit 
questionnaire
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of detection and treatment at baseline, highly sensitive 
and non-specific coding criteria, detailed in table 4, were 
adopted and used for the outcomes’ numerators. These 
criteria were informed by WHO’s mhGAP guidelines.7
Outcome assessors (TR, SS and SDR) independently 
double-coded the outcomes for detection (yes/no) and 
treatment (Yes/No) with 99% initial scoring agreement. 
Disagreements were resolved through further discussion.
Analysis
First, the sociodemographic characteristics and mental 
health screening scores of participants were summarised 
Table 4 Criteria used to assess detection and treatment of depression and alcohol use disorders in the PRIME facility 
detection study, 2013–2014
Detection of depression Treatment of depression
Included:
 ► Diagnosis of ‘depression’
 ► Diagnosis of ‘stress’, ‘distress’, ‘behavioural problem’, 
‘mental disorder’ or ‘psychiatric problem’
 ► Diagnosis assumed if unambiguous depression treatment 
given
Excluded:
 ► Diagnosis of ‘anxiety’, ‘insomnia’, ‘tension headache’, 
‘stress headache’, ‘schizophrenia’, ‘epilepsy’, ‘bipolar’, 
‘central nervous system problem’
Included:
 ► Prescription of SSRI (eg, fluoxetine)
 ► Referral to a mental health specialist
 ► Advice on stress reduction or management—only with 
depression diagnosis
 ► Prescription of tricyclic antidepressant (eg, amitriptyline) 
only with depression diagnosis
 ► Referral to counselling or talking treatment—only with 
depression diagnosis
Excluded:
 ► Diazepam prescription
 ► Non-specific referrals (eg, ‘hospital’)
Detection of alcohol use disorder Treatment of alcohol use disorder
Included:
 ► Diagnosis of ‘AUD’, ‘alcohol problem’ or ‘drinking problem’
 ► Diagnosis assumed if unambiguous AUD treatment given
Excluded:
 ► Drug abuse or other substance use problems
Included:
 ► Referral to a mental health or addictions specialist
 ► Prescription of diazepam or vitamin B—only with AUD 
diagnosis
 ► Counselling or talking treatment—only with AUD diagnosis
Excluded:
 ► Non-specific referrals (eg, ‘hospital’)
AUD, alcohol use disorder; SSRI, selective serotonin reuptake inhibitor,
Table 3 Screening interview sections for PRIME facility detection study, 2013–2014
Section Items, n Source
Part 1
  Basic demographic characteristics 5 Purpose-built for PRIME
  Alcohol use disorder screening 10 Alcohol Use Disorder Identification Test 41
  Alcohol: recent treatment history and 
intentions
23 Purpose-built for PRIME
  Alcohol: internalised stigma 20 Adapted from the Composite International Diagnostic Interview 
Services module42 and the Barriers to Access to Care Evaluation 
Scale43
  Depression screening 9 Patient’s Health Questionnaire44
  Depression symptoms in the past 12 months 1 Purpose-built for PRIME
  Depression: recent treatment history and 
intentions
23 Purpose-built for PRIME
  Depression: internalised stigma 20 Adapted from the Composite International Diagnostic Interview 
Services module42 and the Barriers to Access to Care Evaluation 
Scale43
  Suicidality 7 Adapted from the Composite International Diagnostic Interview 
suicidality module42
Part 2
  Disability 12 WHO Disability Assessment Schedule V.2.045
  Detailed sociodemographic characteristics 18 Purpose-built for PRIME
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by presenting the median and IQR for continuous 
measures and counts and percentages for categorical 
measures. Second, for depression screen-positive partic-
ipants, the numbers and proportions who had outcome 
data were detected for depression and who had initia-
tion of minimally adequate evidence-based treatment 
were reported. The same figures were reported for AUD 
screen-positive participants and AUD. Finally, depres-
sion and AUD detection figures are reported for partic-
ipants who were depression and AUD screen-negative 
and who did not have depression symptoms over the past 
12 months. These latter figures are indicators—though 
not definitive evidence—for either misdiagnosis or 
overdiagnosis. All analyses were conducted in Stata 14.1 
(StataCorp), and stratified by country. (see online supple-
mental file ‘stata do file  code. docx’)
ethics
All participants gave written or verbal informed consent 
prior to being interviewed (table 2). The informed 
consent form made clear there would be no negative 
effects for non-participation. In South Africa, participants 
were provided a 30 rand (US$~2.80) supermarket voucher 
as a token of appreciation. In all countries, participants 
who endorsed questionnaire items about suicidality were 
referred to a provider in the clinic.
The institutional review boards of the WHO (Geneva, 
Switzerland), University of Cape Town (South Africa), 
College of Health Sciences of Addis Ababa University 
(Ethiopia), Indian Council of Medical Research (New 
Delhi, India), Sangath (Goa, India), Nepal Health 
Research Council (Kathmandu, Nepal), Makerere 
University (Kampala, Uganda) and the National Council 
of Science and Technology (Kampala, Uganda) reviewed 
and approved the protocols and informed consent proce-
dures for this study.
Patient involvement
The PRIME interventions and evaluations were informed 
through Theory of Change workshops held in each 
country.28 These workshops included national-level and 
district-level representatives, health service providers and, 
in some countries, mental health service users.
results
The demographic and mental health screening charac-
teristics of participants are detailed in table 5.
Ages ranged from a median of 28 years in Uganda to 
46 years in South Africa. The majority of participants in 
all countries were female, from 51% in India to 79% in 
Uganda. The proportion of participants who screened 
positive for depression ranged between 20% in India to 
4.2% in Uganda, for depression symptoms in the past 12 
months ranged between 8% in Uganda to 14% in India, 
and for AUDIT between 1% in Uganda and 16% in Ethi-
opia. These probable cases were asked to complete the 
Exit interview and/or their clinicians asked to complete a 
consultation form. Outcome data were available for 96% 
of these participants (from clinical consultation forms or 
exit questionnaires), though exit questionnaire comple-
tion was lower for depression screen-positive participants 
in Uganda (48/80, 60%), and AUD screen-positive partic-
ipants in South Africa (38/43, 90%) and Uganda (18/23, 
78%), respectively. Non-completion was primarily due to 
participants having to leave the clinic immediately or the 
Table 5 Demographic and mental health characteristics for facility detection survey participants, 2013–2014
Country site
(sample size)
Ethiopia (n=1014)
Median (IQR) or 
n (%)
India (n=760)
Median (IQR) or 
n (%)
Nepal*
(n=1252) Median 
(IQR) or n (%)
South Africa 
(n=1322) Median 
(IQR) or n (%)
Uganda (n=1893) 
Median (IQR) or 
n (%)
Age, years 30 (23–45) 37 (27–51) 36 (27–50) 46 (37–56) 28 (22–37)
Female 551 (54.3) 386 (50.8) 813 (64.9) 992 (75.0) 1500 (79.2)
Education
  Less than primary 692 (68.3) 381 (50.1) 444 (35.5) 308 (23.3) 174 (9.2)
  Primary 230 (22.7) 186 (24.5) 253 (20.2) 829 (62.7) 1113 (58.8)
  Secondary or more 91 (9.0) 193 (25.4) 555 (44.3) 185 (14.0) 606 (32.0)
PHQ-9 score 4 (1–7) 6 (4–9) 4 (2–7) 3 (1–6) 2 (1–4)
PHQ-9 positive† 117 (11.5) 153 (20.1) 186 (14.9) 107 (8.1) 80 (4.2)
Depression symptoms 
in past 12 months 
110 (14.5) 174 (13.9) 157 (11.9) 159 (8.4)
AUDIT score 2 (0–5) 0 (0–0) 0 (0–1) 0 (0–4) 0 (0–0)
Alcohol abstinent 275 (27.1) 659 (86.7) 849 (67.8) 724 (54.8) 1475 (77.9)
AUDIT positive 166 (16.4) 35 (4.6) 92 (7.3) 43 (3.2) 23 (1.2)
Dependent alcohol use 37 (3.6) 3 (0.4) 32 (2.6) 21 (1.6) 2 (0.1)
*Excluding 222 patients from two clinics.
AUDIT, Alcohol Use Disorder Identification Test; PHQ, Patient's Health Questionnaire,
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interviewer being unable to locate the participant after 
their consultation.
The proportions of screen-positive participants who 
were detected and who started treatment are presented 
table 6.
Among depression screen-positive participants, detec-
tion of depression ranged from 0% in India to 11.7% in 
Nepal. Small proportions of screen-positive participants 
received treatment (0% in Ethiopia, India and South 
Africa to 4.2% in Uganda). Among AUD screen-positive 
participants, detection of AUD ranged from 0% in Ethi-
opia and India to 7.8% in Nepal. Treatment was 0% in all 
countries aside Nepal, where it was 2.2%.
For probable non-cases, detection of depression ranged 
from 0/557 (0.0%) in India to 3/74 (4.0%) in Nepal, and 
detection of AUD ranged from 0/557 (0.0%) in India 
to 2/74 (2.7%) in Nepal. Treatment was almost entirely 
absent (see table 7).
DisCussiOn
This study establishes the magnitude of the detection gap 
for adults attending primary care in diverse LMIC settings. 
There were low levels of detection of depression from 
screen-positive participants in Ethiopia, Nepal, South 
Africa and Uganda and no detection in India. There was 
no detection of AUD among screen-positive participants 
outside Nepal and Uganda. Conversely, there was almost 
no evidence of misdiagnosis or overdiagnosis of depres-
sion or AUD among participants who screened negative.
The detection figures observed here are substantially 
lower than the average figures found by Mitchell et al 
for detection of depression (47%) and for AUD (42%) 
by primary care providers in high-income countries.13 14 
As studies of clinical detection in LMIC settings were not 
available for these meta-analyses, this study fills a key gap 
in our understanding of the detection gap globally. The 
consistency of findings across these five diverse settings 
likely provides insight across LMIC settings generally. The 
health service organisations in this study varied consid-
erably in catchment size, services offered and provider 
types (table 1), and facility attendees varied considerably 
by age, sex, educational attainment and symptom severity 
(table 5). Yet detection was consistently poor. These find-
ings provide insight into how the population-level treat-
ment gap in LMIC is at least partially attributable to a 
facility-level detection gap.
Table 6 Detection and treatment among screen-positive adults in PRIME implementation clinics, 2013–2014
Country site Ethiopia India Nepal South Africa Uganda
Depression
  Outcome data collected/screen 
positive
117/117 153/153 179/186 103/107 48/80
  Detected, n (%, 95% CI) 12/117
(10.3, 5.9 to 17.2)
0/153
(0.0)
21/179
(11.7, 7.8 to 17.3)
6/103
(5.8, 2.6 to 12.4)
2/48
(4.2, 1.0 to 15.4)
  Treatment initiated, n (%, 95% CI) 0/117
(0.0)
0/153
(0.0)
1/179
(0.5, 0.0 to 3.9)
0/103
(0.0)
2/48
(4.2, 1.0 to 15.4)
Alcohol use disorder
  Outcome data collected/screen 
positive
166/166 35/35 90/92 38/43 18/23
  Detected, n (%, 95% CI) 0/166
(0.0)
0/35
(0.0)
7/90
(7.8, 3.7 to 15.6)
0/38
(0.0)
1/18
(5.6, 0.7 to 32.2)
  Treatment initiated, n (%, 95% CI) 0/116
(0.0)
0/35
(0.0)
2/90
(2.2, 0.5 to 8.6)
0/38
(0.0)
0/18
(0.0)
Table 7 Detection and treatment among probable non-cases in PRIME implementation clinics, 2013–2014
Country site (# depression and 
alcohol use disorder screen-
negative and no depression 
symptoms in 12 months)
Ethiopia
(n=752)
India
(n=557)
Nepal
(n=74)
South Africa
(n=113)
Uganda
(n=332)
Depression
  Detected, n (%) 16/752 (2.1) 0/557 (0.0) 3/74 (4.1) 4/113 (3.5) 2/332 (0.6)
  Treatment initiated, n (%) 0/752 (0.0) 0/557 (0.0) 0/74 (0.0) 3/113 (2.6) 1/332 (0.3)
Alcohol use disorder
  Detected, n (%) 0/752 (0.0) 0/557 (0.0) 2/74 (2.7) 2/113 (1.8) 1/332 (0.3)
  Treatment initiated, n (%) 0/752 (0.0) 0/557 (0.0) 0/74 (0.0) 0/113 (0.0) 1/332 (0.3)
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While detection levels were low, the facility-level treat-
ment gap approached 100% in most settings. The treat-
ment outcome definitions used here were broad and 
included provision of advice or referrals to specialist care, 
both of which clinicians were able to dispense prior to 
implementation of the PRIME mental health care plans. 
The first barrier for providing treatment at the health 
facility is detection, and, as reported above, across all 
settings detection levels were extremely low. The findings 
of this study indicate consistent missed opportunities for 
providing evidence-based care across these diverse LMIC 
settings. Improving clinical detection and treatment of 
depression and AUD by primary care providers remains 
an area where intervention development is required; the 
PRIME consortium will evaluate its own interventions—
the plans for which have described in detail29–33—in 
follow-ups to this report.
The PRIME Facility Detection study uses widely vali-
dated screening tools to identify probable cases. While 
diagnostic interviews are the gold standard for identifying 
cases, screening tools are usable by trained interviewers 
rather than clinicians, and so the methods used here are 
more easily replicable for monitoring and evaluation 
activities in other LMIC settings. Our outcome data were 
collected directly from the participants and clinicians 
rather than from a health management information 
system, which is also a replicable monitoring method for 
LMIC settings.
There are several limitations to our study. First, 
screening tools (PHQ-9 and AUDIT) were used to iden-
tify probable cases of depression and AUD; an unknown 
number of screen-positive cases are actually false positive 
cases. Further, a 100% detection figure is not a desirable 
goal as it indicates diagnosis among false positive cases. 
Screening misclassification is likely to be similar in the 
follow-up round, and so the denominators for detec-
tion and treatment are equally biased across rounds 
and allow a valid comparison across time to be made. 
Second, non-random sampling was used to select patients 
in some countries. While the samples may not be repre-
sentative of the facility-attending population, the same 
sampling plan will be used in follow-up rounds, enabling 
valid comparisons for the study’s primary findings. And, 
given the non-random sampling and use of screening 
tools it is not appropriate to interpret the proportions 
of participants who screen positive as prevalence figures 
for cross-country comparisons. The loss to follow-up for 
screen-positive participants in Nepal, South Africa and 
Uganda could result in biased findings as the diagnostic 
characteristics of lost participants are unknown.
A third limitation concerns the outcome definitions for 
detection and treatment. Given the limitations of using 
patient-reported and clinician-reported data, with issues 
around recall and specificity, we opted to use extremely 
sensitive yet non-specific thresholds of evidence for 
coding detection or treatment as having occurred. The 
detection and treatment figures reported here should 
therefore be regarded as the upper bound of possibility: 
some of those coded as having been detected with depres-
sion may have other mental health disorders, and some 
of those coded as having treatment may not have what 
is considered to be minimally adequate evidence-based 
care. Again, the bias due to these misclassifications will be 
equal in the follow-up round. Use of cross-country coding 
criteria facilitates comparisons across diverse settings, 
and in future reports each country can use these criteria 
and/or develop their own more locally appropriate and 
specific criteria. This process has been completed in 
Sodo District, Ethiopia, where detection outcomes have 
been reported separately for using specific criteria for 
depression and non-specific criteria for common mental 
disorder.34
We plan to repeat this survey in each of the implemen-
tation sites. By comparing the baseline versus follow-up 
figures within each country, we will be able to determine 
whether the level of detection and level of initiation of 
evidence-based treatment for depression and for AUD has 
increased after implementing mental health care plans. 
Further to this we will compare the change in detection 
among probable non-cases (table 7), which is an indi-
cator of inappropriate diagnosis; district health manager 
can use two detection figures to recalibrate their training 
and supervision systems. Also using follow-up data, we 
will also be able to assess whether the improved detection 
and improved treatment provision is equitable by age, sex 
and other socioeconomic factors. And, with the help of 
Theory of Change framework and process evaluation data 
collected over the implementation phase,17 we will try to 
explain the reasons for improvement/non-improvement 
of detection and initiation of treatment for depression 
and for AUD, along identifying with the factors relating 
to detection. As each country developed its own Theory 
of Change framework, it will be possible to contrast five 
frameworks with five sets of follow-up findings, and then 
to identify the essential characteristics of an effective 
strategy to improve detection.
Further research can identify the patient-level, clini-
cian-level and system-level characteristics associated with 
detection as a means of further refining interventions. 
Some of these characteristics are already potential targets 
for intervention and have been identified in previous 
studies: on the patient level, those who have higher 
level of perceived need35 and lower levels of internalised 
stigma13 14 are more likely to receive a diagnosis. On the 
clinician level, detection improves with longer consulta-
tion time,36 37 adequate training, a stronger therapeutic 
alliance13 and with contractual incentives.38 And on the 
health system level, detection is likely to improve with the 
availability of medications and health providers at PHC 
level who have the authority to prescribe psychotropic 
medication, as well as referral pathways to counsellors. 
Also important are buy-in and support from leadership 
who give priority to mental health,1 governance and 
supervisory structures to develop and execute stan-
dardised protocols,39 and a functional health manage-
ment information system40 to monitor and feed back 
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on clinical activity. A combination of these patient-level, 
clinician-level and system-level characteristics may explain 
some of the substantially lower detection figures for 
depression and AUD found here from our LMIC settings 
compared with those found in meta-analyses by Mitchell 
et al in HIC settings.
COnClusiOn
The findings of this study suggest large detection and 
treatment gaps for adult primary care patients, which are 
likely contributors to the population-level mental health 
treatment gap in LMIC. Primary care centres remain 
unfulfilled intervention points for reducing the popula-
tion-level burden of disease in LMIC.
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